Although we did not find urinary CD80 and serum suPAR to be relevant biomarkers diagnostic or assess the response to immunosuppressive treatment of MCD or FSGS, the fact that we evaluated them in various glomerulopathies, as well as in healthy individuals, allowed us to identify a series of correlations, such as those suggesting that urinary CD80 is a marker of podocyte injury and that suPAR is nonspecific in glomerulopathies. Here, CD80 is linked to lipoprotein glomerulopathy.